TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7502550
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (750 mg per day)
Study: 7502550
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (750 mg per day) + Simvastatin (20 mg per day)
Study: 7502550
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg per day)
Study: 30352226
Drug: Binocular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binocular treatment with the dichoptic binocular Dig Rush iPad game (1 hour per day, 5 days per week) for 8 weeks
Study: 30352226
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of binocular treatment vs. control
Study: 29225440
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch use
Study: 24069481
Drug: Twice-daily application
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily application of the plant-based repellent Zanzarin
Study: 21771745
Drug: Mixed oral
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed oral nutritional supplements containing B‐group vitamins
Study: 19448230
Drug: i.t. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. morphine (4 microg/kg)
Study: 19448230
Drug: i.t. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. morphine and clonidine (1 microg/kg)
Study: 9213082
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of sulpiride
Study: 7960687
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg, once nightly for 4 weeks
Study: 23208457
Drug: Transtympanic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic steroid injection plus conventional steroid treatment (TR group, n=27)
Study: 23208457
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid treatment (Control group, n=26)
Study: 20650039
Drug: Non-concurrent amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-concurrent amlodipine dosing (simvastatin at 7:00 PM followed by amlodipine at 11:00 PM)
Study: 20650039
Drug: Concurrent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent dosing (both drugs at 7:00 PM)
Study: 20650039
Drug: Non-concurrent amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-concurrent amlodipine dosing
Study: 20650039
Drug: Concurrent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent dosing
Study: 20650039
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (non-concurrent and concurrent)
Study: 17764004
Drug: Self-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-therapy
Study: 8806331
Drug: Prehospital thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital thrombolytic therapy (recombinant tissue plasminogen activator)
Study: 8806331
Drug: Hospital thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital thrombolytic therapy (recombinant tissue plasminogen activator)
Study: 8806331
Drug: Prehospital thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital thrombolytic therapy
Study: 8806331
Drug: Hospital thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital thrombolytic therapy
Study: 8806331
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy within < 70 minutes from symptom onset
Study: 8806331
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy after 70 minutes from symptom onset
Study: 6397969
Drug: De-Nol liquid
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-Nol liquid (4 X 5 ml)
Study: 6397969
Drug: Sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4 X 1 g)
Study: 6397969
Drug: Pirenzepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (3 X 50 mg)
Study: 30955915
Drug: Tipapkinogen sovacivec
Normalized name: Tipapkinogene sovacivec
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipapkinogen sovacivec (TS) vaccine
Study: 25099983
Drug: Live saxophone
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live saxophone music therapy for 30 minutes
Study: 21924651
Drug: Azithromycin monotherapy
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin monotherapy orally
Study: 21924651
Drug: Azithromycin in
Normalized name: azithromycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin in combination with rifampin orally
Study: 20433566
Drug: New daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: New daytime at-home bleaching system (28% carbamide peroxide gel) with a non-custom-fit tray for 20 minutes
Study: 20433566
Drug: Conventional overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional overnight at-home bleaching system (10% carbamide peroxide gel) with a custom-fit tray for 6 to 8 hours
Study: 16189335
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg x kg(‐1) ketamine (Group K)
Study: 16189335
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg x kg(‐1) ketamine and 0.25% bupivacaine (Group BK)
Study: 12378045
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg oral ascorbic acid (AA) preoperatively
Study: 10434238
Drug: Bosentan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (500 mg twice daily for 10 days)
Study: 10434238
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 10 days)
Study: 1971741
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg (positive control)
Study: 29412076
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (BR; ∼800 mg/d)
Study: 29412076
Drug: Nitrate-depleted beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted beetroot juice (PLA; ∼0.5 mg/d)
Study: 12034031
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) monotherapy
Study: 18030234
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus lamivudine combination therapy
Study: 12043854
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.5 mg twice daily
Study: 12798837
Drug: Management group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management group (daily weight monitoring)
Study: 7560229
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and alcohol solutions
Study: 2020505
Drug: Soy-based, lactose-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based, lactose-free formula alternating with oral rehydration solution (early feeding)
Study: 2020505
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution alone (control group)
Study: 6760074
Drug: H1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1 antagonist (diphenhydramine 50 mg iv)
Study: 6760074
Drug: H2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2 antagonist (cimetidine 300 mg iv)
Study: 21360596
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg, single oral dose)
Study: 19532050
Drug: New ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: New ART agents and fixed-dose combinations
Study: 15122774
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation (n = 20)
Study: 9116392
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate therapy (n = 61)
Study: 6365873
Drug: Imipenem-cilastatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (250 mg 6 hourly iv)
Study: 6365873
Drug: Cefazolin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1000 mg 6 hourly iv)
Study: 26454322
Drug: Intravenous haemocoagulase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous haemocoagulase
Study: 15860476
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention consisting of six sessions and maintenance phase with one home and three brief telephone sessions
Study: 8558671
Drug: 5 ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml. 1% lidocaine
Study: 8558671
Drug: 5 ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml. saline (0.9% sodium chloride)
Study: 1678700
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg kg‐1)
Study: 1678700
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg kg‐1)
Study: 6389815
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin given by mouth in divided dosage
Study: 31617926
Drug: Active interventions
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active interventions (physical exercise, nutritional enhancement, cognitive training, combined treatment)
Study: 24354913
Drug: Linguistic agency
Normalized name: ALCOHOL 75 mL in 100 g TOPICAL CLOTH [Greenfield Agencies Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linguistic agency assigned to HPV (e.g., 'HPV preys on millions of people')
Study: 24354913
Drug: Linguistic agency
Normalized name: ALCOHOL 75 mL in 100 g TOPICAL CLOTH [Greenfield Agencies Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linguistic agency assigned to vaccination (e.g., 'Vaccination guards people')
Study: 22405597
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) for 2 years
Study: 20670438
Drug: Intracarpal injections
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracarpal injections of 1 ml triamcinolonacetonide 10 mg/ml (TCA)
Study: 20670438
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml NaCl (placebo)
Study: 17379125
Drug: Traditional tidal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional tidal volume ventilation (V(T), 10 mL/kg)
Study: 17379125
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (V(T), 6 mL/kg)
Study: 17378787
Drug: TCI-propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI-propofol and intravenously administered ketamine (n=9)
Study: 9116609
Drug: i.v. acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. acyclovir 500 mg/m2 three times a day from 5 days before transplant to 30 days after transplant followed by oral acyclovir 800 mg four times a day for a further 6 months
Study: 9116609
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral acyclovir four times a day followed by placebo (control)
Study: 3921097
Drug: Myringotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myringotomy and antibiotics combined
Study: 3921097
Drug: Nose drops
Normalized name: Nose Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose drops and analgesics
Study: 1097603
Drug: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine, 40 mg daily
Study: 31232274
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of nifedipine GITS 60 mg and candesartan 32 mg
Study: 31232274
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of nifedipine and candesartan
Study: 30279197
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (SAPT) - aspirin only
Study: 30279197
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) for an additional six months
Study: 24356620
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) 500 µg q3w
Study: 19942640
Drug: 520 mg
Normalized name: aspirin 520 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 520 mg cocoa flavanols (CF)
Study: 19942640
Drug: 994 mg
Normalized name: petrolatum 0.994 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 994 mg cocoa flavanols (CF)
Study: 12045677
Drug: Chronic suppressive
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic suppressive fluconazole therapy
Study: 12045677
Drug: Episodic fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Episodic fluconazole therapy
Study: 8545290
Drug: Nilvadipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (4 mg)
Study: 12811943
Drug: Protein-rich liquid
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich liquid supplementation with anabolic steroid
Study: 6611964
Drug: 15-methyl PGF2
Normalized name: 15-methyl-pgf2.alpha.
DrugBank: Carboprost (DB19356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-methyl PGF2 alpha with indomethacin suppositories before and during PG induction
Study: 24911423
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral therapy (CBT) intervention for 8 weeks
Study: 19711113
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment for 12 months
Study: 12127707
Drug: Lomefloxacin (LOMX)
DrugBank: Lomefloxacin (DB00978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomefloxacin (LOMX) 400 mg once daily
Study: 12127707
Drug: Ciprofloxacin (CIPX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIPX) 500 mg twice daily
Study: 9771414
Drug: Lipid solution
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid solution (1 ml/minute for 30 minutes)
Study: 9771414
Drug: Protein solution
Normalized name: Plasma protein solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein solution (4.18 J/ml)
Study: 9771414
Drug: Non-absorbable electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable electrolyte solution containing polyethylene glycol
Study: 7934538
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil)
Study: 3282033
Drug: Fluorouracil (5‐FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5‐FU) 15 mg/kg/wk
Study: 3282033
Drug: Fluorouracil (5‐FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5‐FU) plus cisplatin (60 mg/m2 every 3 weeks)
Study: 30807835
Drug: ICG-based adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-based adjunctive antimicrobial photodynamic therapy (aPDT) with perio green® 0.1 mg/ml and diode laser at 808 nm (100 mW at 2 kHz)
Study: 18179308
Drug: Multi-Family Psychoeducation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Family Psychoeducation Groups (MFPGs), 8-session manual-driven treatment as an adjunct to current medications and psychotherapy.
Study: 16306721
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous opioid
Study: 30574864
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of gemigliptin 50 mg and metformin 500 mg
Study: 30574864
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of gemigliptin 50 mg and metformin 500 mg
Study: 30664989
Drug: Chemotherapy (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (up to 6 cycles of topotecan or re-induction of initial chemotherapy)
Study: 28387891
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (intramuscular injection before operation)
Study: 28387891
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative intramuscular injection (control group)
Study: 19706089
Drug: pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimecrolimus 1% cream plus microdermabrasion
Study: 19706089
Drug: pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimecrolimus 1% cream alone
Study: 15561650
Drug: MTZ/CTX 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ/CTX 1 g once daily
Study: 15561650
Drug: T/C 3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/C 3.1 g every 6 hours
Study: 11557914
Drug: Reboxetine 2
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 2 mg
Study: 11557914
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg
Study: 11557914
Drug: Reboxetine 6
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 6 mg
Study: 11557914
Drug: Reboxetine 6
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 6 mg with 200 mg ketoconazole
Study: 9631989
Drug: Fluconazole 300
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 300 mg once weekly
Study: 9631989
Drug: Fluconazole 450
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 450 mg once weekly
Study: 28941842
Drug: Cold gel
Normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold gel packs
Study: 26939316
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupoint application of jieyu plaster and acupuncture
Study: 19749461
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (exact dosage not specified)
Study: 10363732
Drug: Arthrotec 75
Normalized name: Arthrotec 75 Delayed-Release Tablet
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arthrotec 75 (diclofenac sodium 75 mg-misoprostol 200 microg) administered twice daily
Study: 10363732
Drug: nabumetone 1500
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nabumetone 1500 mg administered once daily
Study: 1952710
Drug: Tixocortol-neomycin combination
Normalized name: TIXOCORTOL
DrugBank: Tixocortol (DB09091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tixocortol-neomycin combination (Pivalone-Neomycin nasal suspension)
Study: 1952710
Drug: Placebo (vehicle:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle: N‐cetylpyridinium chloride, sodium chloride, sodium hydroxide solution, benzyl alcohol, purified water, monosodium phosphate)
Study: 30888584
Drug: Cholecalciferol (4800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (4800 IU/daily)
Study: 26742487
Drug: Alternative immunosuppressive
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative immunosuppressive scheme (reduced cyclosporine dosage and substituted azathioprine for mycophenolate mofetil) in group 2
Study: 26742487
Drug: Initial immunosuppressive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial immunosuppressive scheme (azathioprine, cyclosporine, and steroids) in group 1
Study: 23681940
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 10–20 mg/kg/day
Study: 18415773
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate 2 mL (Hyalgan 10.3 mg/mL)
Study: 18415773
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 20 mL (distention)
Study: 18415773
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 2 mL (placebo)
Study: 15778423
Drug: Ranolazine in
Normalized name: Product containing ranolazine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine in combination with diltiazem or simvastatin
Study: 7540705
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta-sitosterol three times per day